The nucleotide sequences of bla AmpC genes of E. coli EC2 have been deposited in the EMBL nucleotide sequence database under accession number EU497239.
AmpC-EC2 is a wild-type cephalosporinase, whereas AmpC-EC2-S287N, AmpC-EC2-E219K, AmpC-EC2-N346I and AmpC-EC2-V298L are variants harbouring the S287N, E219K, N346I and V298L amino acid substitutions, respectively.
Sir, There has been substantial recent controversy regarding the use of ezetimibe, a cholesterol-lowering agent that blocks intestinal absorption of cholesterol. The results of the ENHANCE trial failed to show a benefit of adding ezetimibe to statin therapy. 1, 2 Specifically, in patients with familial hypercholesterolaemia, combined therapy with ezetimibe and simvastatin did not result in a significant difference in changes in intima -media thickness, when compared with simvastatin alone, despite decreases in levels of low-density lipoprotein (LDL)-cholesterol and C-reactive protein in the ezetimibe arm. An accompanying editorial in the New England Journal of Medicine concluded that 'niacin, fibrates, and resins should be considered when diet, exercise, and a statin have failed to achieve the target, with ezetimibe reserved for patients who cannot tolerate these agents'.
3 Subsequent data have similarly failed to show a benefit of ezetimibe and simvastatin over placebo in the SEAS trial, which examined cardiac endpoints in individuals with aortic stenosis. 4, 5 The metabolic complications of HIV and its treatment are well known, and data from small uncontrolled studies have shown that ezetimibe effectively decreases LDL-cholesterol in HIV-infected patients, 6 including those with a poor response to statins 7 and those receiving protease inhibitors (PIs). 8 To investigate this further, we examined the effects of ezetimibe in 29 HIV-infected individuals either alone or in patients receiving statins. Of these individuals, 16 were receiving PI-based highly active antiretroviral therapy (HAART) and 11 were receiving non-nucleoside reverse transcriptase inhibitor (NNRTI)-based HAART with no significant differences in baseline total cholesterol or triglycerides between these groups. A total of 17 patients studied received ezetimibe concurrently with statins. Over 12 weeks, we observed a significant 18.0% reduction in serum total cholesterol (Wilcoxon signed-rank P , 0.01) and a 28.9% decrease in serum triglycerides (Wilcoxon signed-rank P , 0.05) regardless of whether patients received statins or not, or the type of antiretroviral therapy as analysed by the Mann -Whitney U-test (Table 1) . A total of eight patients (40%, McNemar's P , 0.02) had a normalized serum total cholesterol (,5 mmol/L), at the end of the follow-up period. The proportion of patients with normalized serum triglycerides (,2 mmol/L) was not significant. There were no significant differences in reduction of either serum total cholesterol or triglycerides in those receiving ezetimibe alone (n ¼ 12) or in those receiving it with statins (n ¼ 17). One individual stopped as she was attempting to conceive, another due to nausea and anorexia.
Limitations of this work include the small sample size, lack of measurement of LDL levels, length of time patients were exposed to HAART and level of viraemia (which is an independent cause of dyslipidaemia in HIV). However, these data suggest that in patients such as those infected with HIV-1, who are on concomitant medications with effects on the cytochrome P450 system (unlike ezetimibe), we still recommend the use of ezetimibe. This may be either as monotherapy in the second-line treatment of HAART-induced dyslipidaemia, if hypercholesterolaemia is refractory to statins, or if the patient does not tolerate statins. Although the results of the SEAS and ENHANCE trials have diminished confidence in ezetimibe, a larger prospective study in HIV-positive individuals should be undertaken, including intima -media thickness measurements and, if possible, cardiovascular outcomes.
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Sir, It has recently been highlighted that effective antibiotic stewardship is needed in hospitals to assist with minimizing healthcareassociated infections and limiting antimicrobial resistance. 1, 2 Methods that Trusts can use to facilitate appropriate prescribing include providing antibiotic guidelines, auditing antibiotic usage and keeping prescribers updated via an effective education programme.
To evaluate the education programme provided at a mediumsized District General Hospital, I sent a questionnaire to 139 doctors of all grades from the medical and surgical departments. This investigated which methods doctors use to increase their knowledge on antibiotics and asked for their suggestions for improving the education programme. The study was approved by the hospital ethics committee. The response rate was 65.5% (91 returns). The results showed that a variety of methods are used, but the frequency varied (Figure 1) . The most often used was the British National Formulary (BNF). The BNF has previously been shown to be a frequently used resource in a study looking at antibiotic prescribing. 3 Antibiotic guidelines were also used, particularly the Intranet version, which is easily accessible throughout the hospital. Advice from microbiologists and pharmacists as well as seniors and peers was a frequent choice. This shows that doctors value education from their own clinical teams but also seek specialist opinion. Respondents suggested that antimicrobial teams (AMTs) could be introduced into the hospital. AMTs are multidisciplinary and usually I n t r a n e t / e -l e a r n i n g W r i t t e n a n t i b i o t i c g u i d e l i n e s Research letters
